Biosimilars Market By Type (Human growth hormone, Monoclonal antibodies, Insulin, Erythropoietin, Interferon, Granulocyte-Colony Stimulating Factor, Others), Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Growth hormone deficiencies, Others), Industry Trends, Estimation & Forecast, 2017 - 2025
This report studies Biosimilars in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2025.
Biosimilars are biological products that are very similar to a reference biologic and for which there are no clinically meaningful differences in terms of safety, purity, and potency. Biosimilar products are made of complex molecules with high molecular weight produced through genetic engineering in living cells. Biological products can include a wide range of products including vaccines, blood components, gene therapy, tissues, and proteins, like monoclonal antibodies and cell signaling proteins. Biosimilars are just similar because they do not have to be exact copies of the active ingredient, as with small molecule drug generics. Biosimilar therapy is a very effective way of treating diseases like cancer, rheumatoid, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and many autoimmune disorders.
Due to the lower cost, biosimilar medicines are expected to achieve higher demand and drive the growth of the global biosimilars market. The major factor for the growth of global biosimilars market is increasing awareness about biosimilars between the patients and doctors. Additionally, growing number of patients with chronic diseases such as cancer and diabetes are driving the demand for effective biological medicines. The growth of the biosimilars market is hampered due to the lack of regulatory guidelines, consumer brand preference, reluctance of physicians to prescribed biosimilars and the high capital required for research & development. Moreover, high manufacturing cost and difficulty of production, with unclear regulatory policies are some major restraining factors for global biosimilars market. On the other hand, development of bio-better drugs in the emerging economies would act as a future growth opportunity to the biosimilar market.
Biosimilars Market Key Segments
• By Type
o Human growth hormone
o Monoclonal antibodies
o Granulocyte-Colony Stimulating Factor
• By Application
o Blood disorders
o Oncology diseases
o Chronic and autoimmune diseases
o Growth hormone deficiencies
• By Geography
o North America
o Asia Pacific
o Rest of World
Table of Content
o Synthon Pharmaceuticals, Inc.
o Teva Pharmaceutical Industries Ltd.
o LG Life Sciences
o Merck Serono
o Biogen idec, Inc.
What Information does this report contain?
• What was the market size of the biosimilars market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the biosimilars market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?
You may also like
Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs and Over-the-counter-Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semi-Solid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies and Others), and Therapeutic Class (Anti-Glaucoma, Anti-infection, Anti-inflammation, Anti-allergy, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027